Flow cytometric analysis of Human CD161 expression on human PBMC (human peripheral blood mononuclear cells). Human PBMC were stained with Brilliant Violet 421™ Mouse Anti-Human CD4 Antibody and either FITC Mouse IgG1, κ Isotype Control (Left panel) or SDT FITC Mouse Anti-Human CD161 Antibody (Right panel) at 5μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
FITC Mouse Anti-Human CD161 Antibody (S-R581)
FITC Mouse Anti-Human CD161 Antibody (S-R581)
Price:
Regular price
$130.00 SGD
Regular price
Sale price
$130.00 SGD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD161 |
| Synonyms | Killer cell lectin-like receptor subfamily B member 1; C-type lectin domain family 5 member B; HNKR-P1a (NKR-P1A); Natural killer cell surface protein P1A; CLEC5B; NKRP1A; KLRB1 |
| Location | Membrane |
| Accession | Q12918 |
| Clone Number | S-R581 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | human PBMC |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD161, also known as KLRB1 or NKRP1A, is a C-type lectin-like receptor primarily expressed on the surface of natural killer (NK) cells and a subset of T cells, including mucosal-associated invariant T (MAIT) cells and some CD8+ T cells. It is particularly enriched in immune cells located in mucosal sites such as the gut and liver. CD161 binds to its ligand, lectin-like transcript 1 (LLT1, also known as CLEC2D), and this interaction can have both inhibitory and costimulatory effects on immune cells. In the context of cancer immunotherapy, CD161 has been identified as a potential inhibitory receptor in glioma-infiltrating T cells. Its activation by CLEC2D on tumor or immunosuppressive cells can dampen T cell responses against cancer cells. Recent studies suggest that blocking the CD161-CLEC2D interaction may enhance T cell-mediated antitumor activity, making CD161 a promising target for cancer immunotherapy.
Picture
Picture
FC
